[
  {
    "ts": null,
    "headline": "Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset",
    "summary": "Abbott Laboratories (NYSE:ABT) agreed to acquire Exact Sciences for US$21b. The deal is set to reshape Abbott's diagnostics business by adding a broad cancer testing platform. Management is also rolling out changes in the Nutrition segment in response to ongoing operational challenges. For you as an investor, the Exact Sciences deal puts a spotlight on Abbott's push deeper into cancer diagnostics, an area that continues to attract significant attention across healthcare. At the same time,...",
    "url": "https://finnhub.io/api/news?id=42df9644f0d150a3a60825c6fe49b0eb91c6fb4d0bd329379a5680c36422cf15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770063166,
      "headline": "Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset",
      "id": 138336337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) agreed to acquire Exact Sciences for US$21b. The deal is set to reshape Abbott's diagnostics business by adding a broad cancer testing platform. Management is also rolling out changes in the Nutrition segment in response to ongoing operational challenges. For you as an investor, the Exact Sciences deal puts a spotlight on Abbott's push deeper into cancer diagnostics, an area that continues to attract significant attention across healthcare. At the same time,...",
      "url": "https://finnhub.io/api/news?id=42df9644f0d150a3a60825c6fe49b0eb91c6fb4d0bd329379a5680c36422cf15"
    }
  },
  {
    "ts": null,
    "headline": "The Best Dividend King to Buy With $150",
    "summary": "The stock is near its 52-week low.",
    "url": "https://finnhub.io/api/news?id=3a4ae264ffcf752e0360edc1e7f922799f5df0a51ecb0c489d22a139bf89738e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770051900,
      "headline": "The Best Dividend King to Buy With $150",
      "id": 138333779,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The stock is near its 52-week low.",
      "url": "https://finnhub.io/api/news?id=3a4ae264ffcf752e0360edc1e7f922799f5df0a51ecb0c489d22a139bf89738e"
    }
  },
  {
    "ts": null,
    "headline": "NVST or ABT: Which Is the Better Value Stock Right Now?",
    "summary": "NVST vs. ABT: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=af1f53cfaddd49de3f0a617c297ff56837a25564b2f67bc0600bf9e7f5b59253",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770050402,
      "headline": "NVST or ABT: Which Is the Better Value Stock Right Now?",
      "id": 138333780,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "NVST vs. ABT: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=af1f53cfaddd49de3f0a617c297ff56837a25564b2f67bc0600bf9e7f5b59253"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances",
    "summary": "Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice, and flexibility for people living with type 1 and insulin‑requiring type 2 diabetes. These milestones include Medicare access for the MiniMed™ 780G system paired with the Instinct sensor, made by Abbott, FDA clearance for the system's use with ultra rapid‑acting insulins, and clearance of the MiniMed™ 780G system for use with the Instinct sensor for insul",
    "url": "https://finnhub.io/api/news?id=01ab13153828e423462768559d833d7cbb1fada717230566040e60ecadfbed8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770041820,
      "headline": "Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances",
      "id": 138332495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that expand access, choice, and flexibility for people living with type 1 and insulin‑requiring type 2 diabetes. These milestones include Medicare access for the MiniMed™ 780G system paired with the Instinct sensor, made by Abbott, FDA clearance for the system's use with ultra rapid‑acting insulins, and clearance of the MiniMed™ 780G system for use with the Instinct sensor for insul",
      "url": "https://finnhub.io/api/news?id=01ab13153828e423462768559d833d7cbb1fada717230566040e60ecadfbed8a"
    }
  },
  {
    "ts": null,
    "headline": "4 Medical Product Stocks to Watch From a Challenging Industry",
    "summary": "The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.",
    "url": "https://finnhub.io/api/news?id=22639bcd2b561a2b5dc2239d4a044ef35777a5c3c313ac136aefaf9ba530598f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770041280,
      "headline": "4 Medical Product Stocks to Watch From a Challenging Industry",
      "id": 138332710,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.",
      "url": "https://finnhub.io/api/news?id=22639bcd2b561a2b5dc2239d4a044ef35777a5c3c313ac136aefaf9ba530598f"
    }
  },
  {
    "ts": null,
    "headline": "Abbott: Long-Term Investment Opportunity For Dividend Growth Investors",
    "summary": "Abbott Laboratories has a great financial position. The long-term debt/equity ratio is 0.3, while the interest coverage ratio is 17. See why ABT stock is a buy.",
    "url": "https://finnhub.io/api/news?id=3b7aeb6f138456a8ca65c61a5a5baae8d6aea24244d1e3bc359a2124c1efff20",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770024600,
      "headline": "Abbott: Long-Term Investment Opportunity For Dividend Growth Investors",
      "id": 138332007,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325784605/image_1325784605.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Abbott Laboratories has a great financial position. The long-term debt/equity ratio is 0.3, while the interest coverage ratio is 17. See why ABT stock is a buy.",
      "url": "https://finnhub.io/api/news?id=3b7aeb6f138456a8ca65c61a5a5baae8d6aea24244d1e3bc359a2124c1efff20"
    }
  }
]